Sagacious Aldose Reductase Inhibition for Treatment of Metabolic Disorders

Abstract

Aldose reductase inhibitors (ARIs) belong to a group of medications designed to target to manage metabolic disorders, including diabetic neuropathy, diabetic cardiomyopathy, and inflammatory complications. These inhibitors block the polyol pathway, a metabolic route responsible for glucose breakdown, which, when over activated, contributes to diabetes related complications. The most prevalent chronic endocrine disease is diabetes mellitus, whose incidence is steadily increasing worldwide. The health is significantly impacted by it, and it is currently among the leading causes of death. Aldose reductase (AR), a key player in the development of problems from diabetes, has been connected in numerous studies to the polyol pathway. One promising therapeutic approach involves thiazolidinedione derivatives, which feature a heterocyclic ring system with a pharmacophore scaffold widely recognized in medicinal chemistry. Initially developed as antidiabetic agents, these compounds act as specific ligands of Peroxisome Proliferator-Activated Receptors (PPARs). Extensive research has uncovered their diverse biological activities and broad therapeutic potential.